Q&A: Commercial veteran Susan Sweeney mobilizes decades of drug launch experience at Amgen
Susan Sweeney spent more than two decades in drug commercialization at Bristol Myers Squibb before moving to Amgen in September 2019, just a few months before the Covid-19 pandemic.
Sweeney, now Amgen’s senior VP of global marketing, access and capabilities, didn’t know of course what was about to happen any more than anyone else, but her longtime drug launch expertise – which included blockbusters like Opdivo and Eliquis – meant she’d weathered more ups and downs in pharma commercialization than most.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,700+ biopharma pros reading Endpoints daily — and it's free.